Drinking on Retatrutide: What 876 Threads Report, What the Pharmacology Could Explain, and Why the Human Data Say Delayed, Not Stronger

Our GLP-1 and alcohol article covers whether the GLP-1 class reduces the desire to drink. This article covers a different question, the one 876 retatrutide threads actually ask: what happens when someone drinks while on it. Three phenomena get reported as one, each with a different level and type of evidence behind it. Purely informative: it advises nobody about drinking, quantities or timing, and calls no combination safe or unsafe.

What 876 threads report

Our Reddit corpus, the 12 months to 6 August 2026, covers 148,085 posts from r/Retatrutide, r/tirzepatidecompound, r/Peptides, r/Biohackers, r/PeptideDiscussion, r/Semaglutide, r/BPC157 and r/sarmsourcetalk: a community report, not a scientific sample. 33,806 posts mention retatrutide, and 876 use explicit alcohol language (alcohol, wine, beer, hangover, drunk, cocktails, sober, drinking; swabs and "drinking water" excluded), 212 with an alcohol word in the title, 805 of them in r/Retatrutide alone (r/Peptides 35, r/Biohackers 22, r/PeptideDiscussion 13, r/tirzepatidecompound 1). Monthly volume rose from 32 posts in August 2025 to 100 to 123 a month from May through July 2026.

The themes inside the 876 overlap, since one post can mention more than one:

That last row deserves its own note. Coded under "tolerance collapse or drunk faster" by strict keyword matching is the single most-upvoted thread in the entire 876: "Reta & alcohol tolerance (a PSA)," 318 upvotes, 138 comments. Across all 876 posts, 5 carry "drunk faster" or "tolerance gone" language against 8 carrying "no buzz" or "cannot get drunk" language, and two of the five are posters repeating a claim they had read rather than reporting their own night. Read in full, it is not a faster-intoxication report: a poster who used to drink at parties without trouble describes a fraction of their former amount, leaving them hungover, and says the drug removed every desire to drink and every pleasure from it, leaving only nausea and sleepiness. A no-buzz-plus-hangover report that tripped the "drunk faster" filter.

Other threads, by title only, no usernames, vendor names or links: "Alcohol and Reta" (130 upvotes, 115 comments) opens with an imperative warning; a casual drinker who had mostly stopped drank at a bachelor party and describes, three days later, two days of diarrhea, a pounding heart, sweating and the worst hangover of their life. "Since beginning Reta I have totally lost interest in alcohol" (94 upvotes, 78 comments): a roughly 15-year regular drinker lost interest over four to six weeks. "Reta should also be approved to treat alcoholism and potentially other addictions" (101 upvotes, 64 comments): "Kills the urge and if it doesn't you feel terrible right after," an extrapolation section 7 returns to. One poster describes a sequence worth naming: a no-buzz-then-sudden-effect report; no completed or published study located has tested that sequence on retatrutide; it is one report, not a finding.

The corpus is not one-sided. Of the 61 posts that mention a hangover, 2 report none: "Zero hangover from reta?" (score 1), and a poster who "didn't get the hangover surprisingly but I heard it's common." The single post claiming many users end up in emergency rooms carries a score of 0, the lowest engagement discussed here. Upvotes select for the dramatic report.

Two human studies, one rat, and a registry with one pending trial

Two published human studies located have given people alcohol under a GLP-1-class drug, and neither used retatrutide.

Breath alcohol rose more slowly in the fixed-dose drug group at 10 minutes (0.021 vs 0.037), 15 minutes (0.013 vs 0.028) and 20 minutes (0.017 vs 0.037), with no difference from 35 to 60 minutes; cumulative exposure was lower (p = 0.008). Felt intoxication showed a group-by-time interaction (p = 0.009), but no single timepoint reached significance, and the cumulative difference was only a trend (p = 0.06). Craving was lower overall; nausea did not differ: a delayed rise, not a smaller high. The group was 60% semaglutide, no retatrutide tested.

In the free-choice RCT, grams consumed fell (beta -0.48, 95% CI -0.85 to -0.11, P = .01) and so did peak breath alcohol (beta -0.46, 95% CI -0.87 to -0.06, P = .03); drinks per drinking day fell (beta -0.41), while average drinks per calendar day and drinking days did not change. Peak breath alcohol fell because people drank less, so this cannot speak to intoxication per drink; no absolute values were reported (NCT05520775).

The one retatrutide-plus-alcohol experiment located is in rats: acute semaglutide, tirzepatide and retatrutide each attenuated the rats' ability to discriminate alcohol's cue, retatrutide only at the top dose, 0.3 mg/kg. Repeated semaglutide held across 15 days, discrimination returning to control three days after stopping; retatrutide and tirzepatide were acute only. The paper calls itself context for clinical observations, not clinical evidence, about its own (rat) species.

The registry, checked 28 August 2026, is close to empty. ClinicalTrials.gov lists 33 retatrutide studies, none naming alcohol, drinking, addiction or substance use disorder; the one keyword hit is a metoprolol interaction trial matched by taxonomy artifact. Two completed drug-interaction trials exist, caffeine/midazolam/warfarin (NCT05445232) and metoprolol (NCT06808802); neither involved alcohol, neither published. EU CTIS lists 9 retatrutide trials, none about alcohol. As of 28 August 2026, one registered trial located is designed to measure alcohol pharmacokinetics on a GLP-1-class drug: NCT07758231, University of Wisconsin-Madison, tirzepatide, five participants, single arm, not yet recruiting, listed start October 2026, primary completion March 2027, outcomes ethanol Cmax, Tmax and elimination rate. A separate review through 2 July 2025 found 33 GLP-1 substance-use trials, 15 on alcohol, across semaglutide, exenatide, tirzepatide, liraglutide, dulaglutide and pemvidutide; retatrutide appeared nowhere (Patil S et al. Addict Behav Rep. 2026;23:100671. PMID 41696398.). As of 28 August 2026, no completed, published or registered hangover-severity study on any GLP-1-class drug was located; the one registered alcohol trial, NCT07758231, is for a different drug and not yet recruiting.

Why a delayed rise can feel like nothing, and then like too much

Ethanol's peak concentration depends heavily on how fast the stomach empties into the small intestine, where absorption happens, and the GLP-1 class slows that, most in early treatment. The tirzepatide label states, verbatim: "The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses. Following a first dose of tirzepatide 5 mg, acetaminophen maximum concentration (Cmax) was reduced by 50%, and the median peak plasma concentration (tmax) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact" (Eli Lilly, Mounjaro prescribing information, section 12.3, DailyMed, retrieved 28 August 2026). One mechanism, mouse only, points the opposite way: slower hepatic ethanol clearance, which would raise rather than lower blood alcohol.

As a hypothesis, not a finding: a delayed rise means the first 20 minutes can feel like nothing ("I can't get drunk on this"); someone who drinks more in response then meets the delayed bolus later ("it slams you"). The 20-person pilot's timing is consistent with the first half; no completed or published study located has tested the second, on retatrutide or any GLP-1-class drug. See our time-course article for how retatrutide's own effects build on a different axis.

Why the next day can be worse than your own baseline

An expert consensus states, verbatim, that "subjective intoxication ... and not BAC, is the most important determinant of hangover severity," and that drinkers "may have relative tolerance to the adverse effects at their regular drinking level," while considerably higher intake, "irrespective of the absolute amount," produces a hangover (Verster JC et al. J Clin Med. 2020;9. PMID 31936502.). Someone whose usual intake has fallen to near zero has, by this account, no regular level left.

Body composition changes the arithmetic behind blood alcohol; direction only, no worked example. The mean forensic distribution factor in 108 men was 0.689 L/kg, SD 0.061 (Gullberg RG et al. Forensic Sci Int. 1994;69(2):119-30. PMID 7813995.); total-body-water methods outperform that fixed factor (Maskell PD et al. Forensic Sci Int. 2020;316:110532. PMID 33099270.). It is not constant: in 50 volunteers with BMI 16 to 36, measured distribution volume per kilogram fell as BMI rose, in both sexes (Maudens KE et al. Forensic Sci Int. 2014;243:74-8. PMID 24846125.), so a person who loses weight gains distribution volume per kilogram while losing kilograms overall.

Eating less shows up in the corpus: 27 of the 876 posts pair an eating-less phrase with an alcohol word, and one poster writes, "I hadn't eaten much beforehand ... I felt the alcohol much faster than usual." The fed-versus-fasted data above give the mechanism; no completed or published study located measures a GLP-1-class user's reduced meal and drinking together.

The drug's own gastrointestinal profile, by arm, is worth placing next to the symptoms posters name (retatrutide phase 2 registry, NCT04881760, adverse events at a 5% threshold, not adjudicated):

The NEJM report calls these dose-related, partially mitigated by a lower starting dose (Jastreboff AM et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315.). The diarrhea, pounding heart and sweating named in "Alcohol and Reta" above sit on top of these, whatever alcohol independently adds.

Heart rate is documented separately for drug and alcohol, not in the same study. The phase 2 paper states dose-dependent increases "peaked at 24 weeks and declined thereafter"; the per-timepoint figures behind that peak sit in a supplementary appendix that is not publicly accessible. A class meta-analysis gives retatrutide a mean increase of 3.46 bpm versus placebo (95% CI 1.74 to 5.18) (Zhang Y et al. Eur J Med Res. 2026;31(1):318. PMID 41582189.); the tirzepatide label reports 2 to 4 bpm against 1 bpm on placebo, with sinus tachycardia (15 bpm or more) in 4.3% on placebo against 4.6%, 5.9% and 10% on the 5, 10 and 15 mg doses. Alcohol has its own effect: across 5,109,185 person-days from 20,968 wearable users, one drink above a person's own average, compared with one drink below it, was associated with a nocturnal resting heart rate 2.8 bpm higher in women and 2.4 bpm higher in men, and heart-rate variability 3.8 and 3.3 ms lower, respectively (Grosicki GJ et al. PLOS Digit Health. 2026;5(3):e0001284. PMID 41801993.; wearable-manufacturer funded, seven of eleven authors its employees). Additive only in arithmetic; no study located has measured them together.

Fluid handling shifts too. In 8 men given 1.2 g/kg ethanol over three evening hours, urine output rose the first three hours, then fell below control from midnight to 6 a.m.; after a morning water load they retained 44% against 12% on the control evening (Taivainen H et al. Alcohol Clin Exp Res. 1995;19(3):759-62. PMID 7573805.); vasopressin did not differ during the diuretic phase, so should not be called suppressed. The class labels separately warn of acute kidney injury from volume depletion, stating, verbatim, "the majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea" (Mounjaro 5.5, verbatim; Ozempic 5.6 carries the same warning in near-identical wording; postmarketing, no rate). No completed or published study located measures the two together.

Blood sugar rarely comes up (4 of the 876 posts). In overnight-fasted men, 48 g of alcohol cut gluconeogenesis 45% against placebo over 5 hours, yet plasma glucose did not fall, because glycogenolysis and peripheral utilization compensated (Siler SQ et al. Am J Physiol. 1998;275(5):E897-907. PMID 9815011.). The class labels place their hypoglycemia warning only alongside insulin or an insulin secretagogue; none of the seven label documents searched mentions drinking.

Expectation is a documented confound, not a dismissal. In a 12-month crossover of statin, placebo and no tablet in 60 people, 90% of the symptom burden attributed to the statin was also produced by placebo; symptom timing could not be read as causation (Howard JP et al. J Am Coll Cardiol. 2021;78(12):1210-1222. PMID 34531021.). Different drug, cited for the expectancy mechanism only; two posters in our corpus cite what they had already seen online before describing their own night. What is drunk matters too: at matched breath alcohol, bourbon produced a worse hangover than vodka in 95 heavy drinkers, though ethanol mattered more than congener content (Rohsenow DJ et al. Alcohol Clin Exp Res. 2010;34(3):509-18. PMID 20028364.).

See side effects and safety profile and heart rate, HRV and fatigue.

What seven label documents searched on 28 August 2026 say about alcohol

None of the four US labels and three EU product-information documents searched mentions drinking. The four US prescribing-information documents (Wegovy, Ozempic, Zepbound, Mounjaro; DailyMed, retrieved 28 August 2026) contain "alcohol" only as "alcohol swab," benzyl alcohol, or "nonalcoholic steatohepatitis" (Wegovy also "non-alcoholic fatty liver disease"); "ethanol" and "alcoholic beverage" return zero hits across all four. The three EU documents (Wegovy 182 pages, Ozempic 143, Mounjaro 202) contain "alcohol" only in the Mounjaro document, and there only as part of "benzyl alcohol": a verified absence, not an inference.

All four US labels carry the same pancreatitis-signal wording, verbatim: "Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists" (Novo Nordisk's adds "including WEGOVY"; Eli Lilly's adds "or ZEPBOUND"). Class language, no alcohol mention. Adjudicated rates, always with their comparator:

Zepbound's two pools are shown together since they share a product; not comparable across different products. A meta-analysis of 62 trials, 66,232 patients, mean follow-up 43.5 weeks, found an overall pancreatitis relative risk of 1.44 (95% CI 1.09 to 1.89, p = 0.009), not significant once stratified by background medication (1.28, 0.87 to 1.87; and 1.37, 0.91 to 2.05); no retatrutide breakout, no alcohol stratification (Wen J et al. Endocrinol Diabetes Metab. 2025;8(5):e70113. PMID 40988099.).

Alcohol has its own relationship to pancreatitis. The ACG guideline lists gallstones (40 to 70%) and alcohol (25 to 35%) as the most common causes, and states alcohol-induced pancreatitis "should not be entertained unless a person has consumed over 5 years moderate or heavy alcohol consumption," generally above 50 g per day, with clinically evident acute pancreatitis in only up to 5% of heavy drinkers (Tenner S et al. Am J Gastroenterol. 2024;119(3):419-437. PMID 38857482.). Two separate bodies of evidence; no completed or published study located measures the combination.

Retatrutide's own numbers, raw counts with denominators, never a rate: one serious acute pancreatitis in the 12 mg arm (1 of 62), none elsewhere including placebo (0 of 70); one acute cholecystitis in an 8 mg arm (1 of 35); one death in the 4 mg arm without a lower starting dose (1 of 33). The trial excluded anyone drinking over 14 units a week (women) or 21 (men), and anyone with prior pancreatitis: a screened population. All four TRIUMPH phase 3 trials, 5,878 participants, are completed with no results posted, no alcohol exclusion in posted eligibility.

On the liver, semaglutide 2.4 mg produced steatohepatitis resolution in 62.9% against 34.3% on placebo, fibrosis improvement 36.8% against 22.4% at 72 weeks, in 800 biopsy-confirmed MASH patients (Sanyal AJ et al. N Engl J Med. 2025;392(21):2089-2099. PMID 40305708.); no alcohol variable reported. A 2026 review states alcohol and cardiometabolic risk "act synergistically rather than additively" on liver inflammation and fibrosis, with the combined condition, MetALD, affecting about 4.1% of adults globally (Díaz LA et al. Nat Rev Gastroenterol Hepatol. 2026. PMID 42613422.); that is alcohol plus metabolic risk generally, not plus a GLP-1-class drug. A completed trial of semaglutide and cagrilintide in alcohol-related liver disease (NCT06409130, primary completion November 2025, study completion January 2026) has no results posted. See GLP-1 safety, physiology and thyroid, cancer and testosterone.

Does drinking stall the weight loss

Ethanol carries about 7.1 kcal per gram, by one widely cited review (Sayon-Orea C et al. Nutr Rev. 2011;69(8):419-31. PMID 21790610.). In a metabolic-chamber crossover in 8 healthy men, ethanol at 25% of energy requirement on top of the diet suppressed lipid oxidation while carbohydrate and protein oxidation were unchanged; habitual ethanol beyond energy needs "probably favors lipid storage and weight gain" (Suter PM et al. N Engl J Med. 1992;326(15):983-7. PMID 1545851.). Intravenous ethanol plus glucose in 6 men found fat oxidation reduced 79%, protein oxidation also reduced (Shelmet JJ et al. J Clin Invest. 1988;81(4):1137-45. PMID 3280601.); the two agree fat oxidation falls, not on how selective it is.

The epidemiology is inconsistent, not one-directional: light-to-moderate intake is generally not linked to weight gain in recent cohorts, while heavier and binge patterns are (Sayon-Orea C et al. Nutr Rev. 2011;69(8):419-31. PMID 21790610.; Traversy G et al. Curr Obes Rep. 2015;4(1):122-30. PMID 25741455.). Alcohol with or before a meal raises food intake within an hour with no measured compensation, and long term "energy ingested as alcohol is additive to energy from other sources," while the same author notes moderate intake may protect against obesity in some cohorts (Yeomans MR. Br J Nutr. 2004;92 Suppl 1:S31-4. PMID 15384320.; Yeomans MR. Physiol Behav. 2010;100(1):82-9. PMID 20096714.). Sleep is contested: one review found alcohol shortens sleep onset and disrupts the second half of the night (Ebrahim IO et al. Alcohol Clin Exp Res. 2013;37(4):539-49. PMID 23347102.), but was formally challenged for flawed design, methods and statistics (Pressman MR et al. Alcohol Clin Exp Res. 2015;39(5):941-3. PMID 25871341.). Next-morning fluid retention, above, can itself read as a scale stall with no change in fat mass.

As of 28 August 2026, no completed or published weight-loss trial of retatrutide, semaglutide or tirzepatide located has analyzed outcomes by alcohol intake, or reported reduced drinking as a contributor (PubMed, ClinicalTrials.gov, EU CTR, checked 28 August 2026). One trial is registered, not reporting: NCT06546384, GLP-1 receptor agonists on alcohol consumption, metabolism and liver parameters in obesity with fatty liver, not yet recruiting, estimated start November 2026, no results posted.

Lost interest, and the leap to "it should be approved for alcoholism"

The reduced-desire experience has class evidence, laid out in our GLP-1 and alcohol article. In short: a 26-week placebo-controlled semaglutide 2.4 mg trial in 108 patients with alcohol use disorder and obesity met its primary endpoint, heavy drinking days falling 41.1 percentage points against 26.4 on placebo, difference -13.7 (95% CI -22.0 to -5.4) (Klausen MK et al. Lancet. 2026;407(10540):1687-1698. PMID 42070571.). A 2026 oral semaglutide trial in 50 patients missed its primary endpoint, craving, though heavy drinking days fell as a secondary outcome (Schacht JP et al. Am J Psychiatry. 2026. PMID 42522065.). A 26-week exenatide trial in 127 patients did not significantly reduce heavy drinking days (Klausen MK et al. JCI Insight. 2022;7. PMID 36066977.). An observational emulation in type 2 diabetes gave hazard ratios for incident alcohol use disorder of 0.47 (95% CI 0.29-0.75) for tirzepatide and 0.68 (0.52-0.89) for semaglutide (Henney AE et al. Diabetes Obes Metab. 2026;28(1):137-150. doi 10.1111/dom.70169), and a 2026 review of five studies calls the evidence "limited and heterogeneous" (Altami IK et al. J Clin Med. 2026;15. PMID 42355949.).

None of it is retatrutide, which appears in no alcohol-use trial located in the registries checked on 28 August 2026; the closest completed trial used pemvidutide, a different GLP-1/glucagon dual agonist, in 100 patients (NCT06987513, completed July 2026, unpublished). The leap from "this helped me want alcohol less" to "this should be an approved addiction treatment," visible above, runs well ahead of any retatrutide-specific data; our GLP-1 and alcohol article covers what has actually been tested, and on which drug.

What a study would have to measure

Nothing above adds up to an answer, since no completed or published study located combines the pieces that would give one. A real test would need a fixed-dose alcohol challenge on retatrutide itself, tracked the way the semaglutide/liraglutide/tirzepatide pilot did; a hangover instrument the next day, not a spontaneous adverse-event report; a population that includes drinkers, not one that excludes anyone over 14 units a week (women) or 21 (men) as retatrutide's own phase 2 trial did; and an arm at each dose, since the gastric-emptying and heart-rate data above both scale with dose and time. As of 28 August 2026, one registered trial located points this way in the class: the five-person, single-arm tirzepatide study, not yet recruiting. Until something like it runs on retatrutide, this article's title stays open, not answered.

Where these compounds sit in our catalog

Frequently asked questions

Sources

1. Quddos F et al. A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. Sci Rep. 2025;15(1):32385. PMID 41093891. https://pubmed.ncbi.nlm.nih.gov/41093891/
2. Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. PMID 39937469. https://pubmed.ncbi.nlm.nih.gov/39937469/
3. ClinicalTrials.gov. NCT05520775, semaglutide alcohol use disorder trial registration. https://clinicaltrials.gov/study/NCT05520775
4. Windram M et al. Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology (Berl). 2026;243(5):1185-1197. PMID 40699363. https://pubmed.ncbi.nlm.nih.gov/40699363/
5. ClinicalTrials.gov. Search of 33 registered retatrutide studies, checked 28 August 2026, no alcohol-related trial located. https://clinicaltrials.gov/search?term=retatrutide
6. ClinicalTrials.gov. NCT05445232, retatrutide drug-interaction trial with caffeine, midazolam and warfarin. https://clinicaltrials.gov/study/NCT05445232
7. ClinicalTrials.gov. NCT06808802, retatrutide drug-interaction trial with metoprolol. https://clinicaltrials.gov/study/NCT06808802
8. EU Clinical Trials Information System. Search of 9 registered retatrutide trials, checked 28 August 2026, no alcohol-related trial located. https://euclinicaltrials.eu
9. ClinicalTrials.gov. NCT07758231, University of Wisconsin-Madison tirzepatide alcohol pharmacokinetics trial, not yet recruiting. https://clinicaltrials.gov/study/NCT07758231
10. Patil S et al. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. Addict Behav Rep. 2026;23:100671. PMID 41696398. https://pubmed.ncbi.nlm.nih.gov/41696398/
11. Jones AW et al. Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. Br J Clin Pharmacol. 1997;44(6):521-6. PMID 9431825. https://pubmed.ncbi.nlm.nih.gov/9431825/
12. Kechagias S et al. Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. Br J Clin Pharmacol. 1999;48(5):728-32. PMID 10594475. https://pubmed.ncbi.nlm.nih.gov/10594475/
13. Eli Lilly. Mounjaro (tirzepatide) prescribing information, section 12.3 and oral-contraceptive coadministration section. DailyMed, retrieved 28 August 2026. https://dailymed.nlm.nih.gov
14. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. PMID 32519795. https://pubmed.ncbi.nlm.nih.gov/32519795/
15. Jensterle M et al. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023;25(4):975-984. PMID 36511825. https://pubmed.ncbi.nlm.nih.gov/36511825/
16. Novo Nordisk. Ozempic (semaglutide) prescribing information, section 12.3. DailyMed, retrieved 28 August 2026. https://dailymed.nlm.nih.gov
17. Urva S et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. PMID 37311727. https://pubmed.ncbi.nlm.nih.gov/37311727/
18. Zahrawi F, Suyavaran A, Banini BA, Mehal WZ. GLP-1 receptor agonism results in reduction in hepatic ethanol metabolism. NPJ Metab Health Dis. 2025;3(1):36. doi 10.1038/s44324-025-00077-y.
19. Strommen M, Dale O, Klockner C, Tylleskar I. Ethanol pharmacokinetics before and after sleeve gastrectomy and Roux-en-Y gastric bypass: a 3 year prospective study (the BAR-TRIAL). Int J Obes. 2026;50(7):1573-1580. doi 10.1038/s41366-026-02113-3; NCT01840020.
20. Verster JC et al. Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover. J Clin Med. 2020;9. PMID 31936502. https://pubmed.ncbi.nlm.nih.gov/31936502/
21. Gullberg RG et al. Guidelines for estimating the amount of alcohol consumed from a single measurement of blood alcohol concentration: re-evaluation of Widmark's equation. Forensic Sci Int. 1994;69(2):119-30. PMID 7813995. https://pubmed.ncbi.nlm.nih.gov/7813995/
22. Maskell PD et al. Total body water is the preferred method to use in forensic blood-alcohol calculations rather than ethanol's volume of distribution. Forensic Sci Int. 2020;316:110532. PMID 33099270. https://pubmed.ncbi.nlm.nih.gov/33099270/
23. Maudens KE et al. The influence of the body mass index (BMI) on the volume of distribution of ethanol. Forensic Sci Int. 2014;243:74-8. PMID 24846125. https://pubmed.ncbi.nlm.nih.gov/24846125/
24. ClinicalTrials.gov. NCT04881760, retatrutide phase 2 dose-ranging trial in obesity, results section, adverse events by arm. https://clinicaltrials.gov/study/NCT04881760
25. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. https://pubmed.ncbi.nlm.nih.gov/37366315/
26. Zhang Y et al. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. Eur J Med Res. 2026;31(1):318. PMID 41582189. https://pubmed.ncbi.nlm.nih.gov/41582189/
27. Eli Lilly. Tirzepatide prescribing information, heart rate and cardiac electrophysiology sections. DailyMed, retrieved 28 August 2026. https://dailymed.nlm.nih.gov
28. Grosicki GJ et al. Real-world effects of alcohol on heart rate, sleep, and physical activity by age and sex. PLOS Digit Health. 2026;5(3):e0001284. PMID 41801993. https://pubmed.ncbi.nlm.nih.gov/41801993/
29. Taivainen H et al. Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication. Alcohol Clin Exp Res. 1995;19(3):759-62. PMID 7573805. https://pubmed.ncbi.nlm.nih.gov/7573805/
30. Novo Nordisk. Ozempic prescribing information, section 5.6, acute kidney injury. DailyMed, retrieved 28 August 2026. https://dailymed.nlm.nih.gov
31. Siler SQ et al. The inhibition of gluconeogenesis following alcohol in humans. Am J Physiol. 1998;275(5):E897-907. PMID 9815011. https://pubmed.ncbi.nlm.nih.gov/9815011/
32. Howard JP et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021;78(12):1210-1222. PMID 34531021. https://pubmed.ncbi.nlm.nih.gov/34531021/
33. Rohsenow DJ et al. Intoxication with bourbon versus vodka: effects on hangover, sleep, and next-day neurocognitive performance in young adults. Alcohol Clin Exp Res. 2010;34(3):509-18. PMID 20028364. https://pubmed.ncbi.nlm.nih.gov/20028364/
34. DailyMed. Wegovy and Ozempic (Novo Nordisk), Zepbound and Mounjaro (Eli Lilly) prescribing information, whole-document alcohol keyword search. Retrieved 28 August 2026. https://dailymed.nlm.nih.gov
35. European Medicines Agency. Wegovy, Ozempic and Mounjaro summary of product characteristics, alcohol keyword search. https://www.ema.europa.eu/en/medicines
36. Wen J et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8(5):e70113. PMID 40988099. https://pubmed.ncbi.nlm.nih.gov/40988099/
37. Tenner S et al. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis. Am J Gastroenterol. 2024;119(3):419-437. PMID 38857482. https://pubmed.ncbi.nlm.nih.gov/38857482/
38. Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID 40305708. https://pubmed.ncbi.nlm.nih.gov/40305708/
39. Díaz LA et al. Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications. Nat Rev Gastroenterol Hepatol. 2026. PMID 42613422. https://pubmed.ncbi.nlm.nih.gov/42613422/
40. ClinicalTrials.gov. NCT06409130, semaglutide and cagrilintide in alcohol-related liver disease, primary completion 21 November 2025, study completion 12 January 2026, no results posted. https://clinicaltrials.gov/study/NCT06409130
41. Sayon-Orea C et al. Alcohol consumption and body weight: a systematic review. Nutr Rev. 2011;69(8):419-31. PMID 21790610. https://pubmed.ncbi.nlm.nih.gov/21790610/
42. Suter PM et al. The effect of ethanol on fat storage in healthy subjects. N Engl J Med. 1992;326(15):983-7. PMID 1545851. https://pubmed.ncbi.nlm.nih.gov/1545851/
43. Shelmet JJ et al. Ethanol causes acute inhibition of carbohydrate, fat, and protein oxidation and insulin resistance. J Clin Invest. 1988;81(4):1137-45. PMID 3280601. https://pubmed.ncbi.nlm.nih.gov/3280601/
44. Traversy G et al. Alcohol Consumption and Obesity: An Update. Curr Obes Rep. 2015;4(1):122-30. PMID 25741455. https://pubmed.ncbi.nlm.nih.gov/25741455/
45. Yeomans MR. Effects of alcohol on food and energy intake in human subjects: evidence for passive and active over-consumption of energy. Br J Nutr. 2004;92 Suppl 1:S31-4. PMID 15384320. https://pubmed.ncbi.nlm.nih.gov/15384320/
46. Yeomans MR. Alcohol, appetite and energy balance: is alcohol intake a risk factor for obesity?. Physiol Behav. 2010;100(1):82-9. PMID 20096714. https://pubmed.ncbi.nlm.nih.gov/20096714/
47. Ebrahim IO et al. Alcohol and sleep I: effects on normal sleep. Alcohol Clin Exp Res. 2013;37(4):539-49. PMID 23347102. https://pubmed.ncbi.nlm.nih.gov/23347102/
48. Pressman MR et al. Alcohol and sleep review: flawed design, methods, and statistics cannot support conclusions. Alcohol Clin Exp Res. 2015;39(5):941-3. PMID 25871341. https://pubmed.ncbi.nlm.nih.gov/25871341/
49. ClinicalTrials.gov. NCT06546384, GLP-1 receptor agonists on alcohol consumption, metabolism and liver parameters in obesity with fatty liver, not yet recruiting, estimated start November 2026, no results posted. https://clinicaltrials.gov/study/NCT06546384
50. Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687-1698. PMID 42070571. https://pubmed.ncbi.nlm.nih.gov/42070571/
51. Schacht JP et al. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2026. PMID 42522065. https://pubmed.ncbi.nlm.nih.gov/42522065/
52. Klausen MK et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7. PMID 36066977. https://pubmed.ncbi.nlm.nih.gov/36066977/
53. Henney AE et al. Diabetes Obes Metab. 2026;28(1):137-150. doi 10.1111/dom.70169.
54. Altami IK et al. Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence. J Clin Med. 2026;15. PMID 42355949. https://pubmed.ncbi.nlm.nih.gov/42355949/
55. ClinicalTrials.gov. NCT06987513, pemvidutide alcohol use disorder trial, completed July 2026, unpublished. https://clinicaltrials.gov/study/NCT06987513
56. Internal analysis of a public Reddit archive, 148,085 posts from r/Retatrutide, r/tirzepatidecompound, r/Peptides, r/Biohackers, r/PeptideDiscussion, r/Semaglutide, r/BPC157 and r/sarmsourcetalk, 12 months to 6 August 2026.

Research use only. Retatrutide, tirzepatide and semaglutide are referenced here for their published research record. Products sold on this site are supplied for laboratory research, not for human or animal administration, and not as medicines. Nothing in this article is drinking, dosing or safety guidance, and nothing here claims that any product is safe, unsafe, or free of interaction with alcohol.